Publications
Featured Publication
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
N Engl J Med 2021; 384:717-726
View
Safety and Efficacy of KarXT (Xanomeline-Trospium) in Schizophrenia in the Phase 3, Randomized, Double-blind, Placebo-controlled EMERGENT-2 Trial
Neuroscience Education Institute (NEI) Congress; 2022 November 3-6.
View
Muscarinic Acetylcholine Receptors for Psychotic Disorders: Bench-side to Clinic
Trends Pharmacol Sci. 2022 Dec;43(12):1098-1112.
View
Safety and Efficacy of KarXT (Xanomeline Trospium) in Patients With Schizophrenia: Results From a Phase 3, Randomised , Double Blind, Placebo Controlled Trial (EMERGENT 2)
European College of Neuropsychopharmacology (ECNP) Congress; 2022 October 15-18.
View
Safety and Efficacy of KarXT (Xanomeline–Trospium) in Patients With Schizophrenia: Results From a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial (EMERGENT-2)
European College of Neuropsychopharmacology (ECNP) Congress; 2022 October 15-18.
View
The Potential of M1 Agonists to Treat Cognitive Impairment: Evidence From a Phase 2 Study of KarXT in Schizophrenia (EMERGENT-1)
2022 Schizophrenia International Research Society (SIRS) Annual Congress. 2022 April 6-10.
View
KarXT Treatment Improves Cognitive Performance in Cognitively Impaired Patients with Schizophrenia: A Post hoc Analysis of the Phase 2 EMERGENT-1 Study
34th European College of Neuropsychopharmacology (ECNP) Congress; 2021 October 2-5.
View
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia
American Journal of Psychiatry 2022; 21101083
View